keyword
MENU ▼
Read by QxMD icon Read
search

comparative efficacy of ppis

keyword
https://www.readbyqxmd.com/read/27907909/egfr-kinase-inhibitors-and-gastric-acid-suppressants-in-egfr-mutant-nsclc-a-retrospective-database-analysis-of-potential-drug-interaction
#1
Nesaretnam Barr Kumarakulasinghe, Nicholas Syn, Yu Yang Soon, Atasha Asmat, Huili Zheng, En Yun Loy, Brendan Pang, Ross Andrew Soo
BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. We assessed the clinical relevance of this potential drug-drug interaction (DDI) in a retrospective cohort of EGFR-mutant NSCLC patients...
November 19, 2016: Oncotarget
https://www.readbyqxmd.com/read/27855401/systematic-review-and-net-work-meta-analysis-of-upper-gastrointestinal-hemorrhage-interventions
#2
Mengyuan Jiang, Pan Chen, Qiang Gao
BACKGROUND/AIMS: Upper gastrointestinal hemorrhage (UGH) is a serious medical condition which affects a large number of individuals. Endoscopic therapy accompanied by medication is a standard approach that is used to improve the prognosis of UGH patients and a few medications have been developed including proton pump inhibitors (PPIs), histamine H2 receptor antagonist (H2RA), somatostatin analogues and tranexamic acid. This study is set to compare the efficacy and safety of various medical interventions that are used to manage upper gastrointestinal bleeding...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27806639/analysis-of-the-cost-effectiveness-of-using-vonoprazan-amoxicillin-clarithromycin-triple-therapy-for-first-line-helicobacter-pylori-eradication
#3
Yusaku Kajihara, Tadashi Shimoyama, Ichiro Mizuki
BACKGROUND: Vonoprazan (VPZ)-based triple therapy has been reported to have greater efficacy than a proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (H. pylori) eradication. However, because VPZ is more expensive than PPIs such as rabeprazole (RPZ), economic evaluation is essential. METHODS: We performed a retrospective study on 209 patients who underwent first-line eradication of H. pylori infection in Fuyoukai Murakami Hospital from 1 March 2015 to 31 March 2016...
November 3, 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27782887/comparison-of-the-effects-of-esomeprazole-40-mg-rabeprazole-20-mg-lansoprazole-30-mg-and-pantoprazole-40-mg-on-intragastr%C3%A4-c-ph-in-extensive-metabolizer-patients-with-gastroesophageal-reflux-disease
#4
Altay Çelebi, Dinçer Aydın, Orhan Kocaman, Buğra Tolga Konduk, Ömer Şentürk, Sadetin Hülagü
BACKGROUND/AIMS: Studies on the therapeutic efficacy of proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) have been recently published. In most of these studies, comparison of only two PPIs have been made. There are few studies on the comparison of four or more PPIs. We aimed to compare the acid inhibitory effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on days 1 and 5 of treatment in patients with GERD, who were extensive metabolizers in regard to the CYP2C19 genotype...
September 2016: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/27737436/association-of-proton-pump-inhibitors-and-capecitabine-efficacy-in-advanced-gastroesophageal-cancer-secondary-analysis-of-the-trio-013-logic-randomized-clinical-trial
#5
Michael P Chu, J Randolph Hecht, Dennis Slamon, Zev A Wainberg, Yung-Jue Bang, Paulo M Hoff, Alberto Sobrero, Shukui Qin, Karen Afenjar, Vincent Houe, Karen King, Sheryl Koski, Karen Mulder, Julie Price Hiller, Andrew Scarfe, Jennifer Spratlin, Yingjie J Huang, Saba Khan-Wasti, Neil Chua, Michael B Sawyer
Importance: Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other oral medications though, it may suffer from drug interactions that could impair its absorption. Objective: To determine if gastric acid suppressants such as proton pump inhibitors (PPIs) may impair capecitabine efficacy. Design, Setting, and Participants: This secondary analysis of TRIO-013, a phase III randomized trial, compares capecitabine and oxaliplatin (CapeOx) with or without lapatinib in 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer (GEC); patients were randomized 1:1 between CapeOx with or without lapatinib...
October 13, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27637911/concomitant-use-of-proton-pump-inhibitors-and-clopidogrel-increases-the-risk-of-adverse-outcomes-in-patients-with-ischemic-stroke-carrying-reduced-function-cyp2c19-2
#6
Xingyang Yi, Zhao Han, Qiang Zhou, Wen Cheng, Jing Lin, Chun Wang
OBJECTIVE: Conflicting data exist as to whether proton-pump inhibitors (PPIs) diminish the efficacy of clopidogrel. The aim of this study was to investigate the association between cytochrome P450 (CYP) genetic variants and clinical adverse outcomes of concomitant use of PPIs and clopidogrel by patients. METHODS: We consecutively enrolled 523 patients with ischemic stroke receiving clopidogrel. Platelet aggregation was measured before and after 7 to 10 days of clopidogrel treatment...
September 16, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27605258/a-randomized-double-blind-active-controlled-multi-center-study-of-ilaprazole-in-the-treatment-of-reflux-esophagitis
#7
Yan Xue, Xianghong Qin, Liya Zhou, Sanren Lin, Ling Wang, Haitang Hu, Jielai Xia
BACKGROUND AND OBJECTIVE: Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Previous studies have indicated ilaprazole to be safer and more effective in treating duodenal ulcers as compared with omeprazole. Being a novel PPI, ilaprazole may be used in the treatment of reflux esophagitis. The purpose of this study was to evaluate the safety and efficacy of ilaprazole tablets in the treatment of reflux esophagitis. METHODS: This study used a randomized, double-blind, multi-center, active-comparison design...
September 7, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27598861/ilaprazole-for-the-treatment-of-gastro-esophageal-reflux
#8
Edoardo Savarino, Andrea Ottonello, Irene Martinucci, Pietro Dulbecco, Vincenzo Savarino
INTRODUCTION: Despite the undoubted benefit of proton pump inhibitors (PPIs), they have several shortcomings, such as a slow onset of action and a remarkable inter-individual variability, that limit the complete success of these drugs. Recently, a new PPI, ilaprazole, has been developed and used in GERD patients. AREAS COVERED: The present review provides an update on the following points: current knowledge of GERD mechanisms; limitations of actual therapies; pharmacokinetic profile and metabolism of ilaprazole; initial studies on the therapeutic efficacy of ilaprazole in GERD...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27581096/the-efficacy-and-safety-of-proton-pump-inhibitors-in-treating-patients-with-non-erosive-reflux-disease-a-network-meta-analysis
#9
Lingxiao Chen, Yujie Chen, Bo Li
Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD). However, less is known about the comparisons among different PPIs and their best dosage. We aimed to synthesize the available evidence through network meta-analysis to investigate the efficacy and safety of different PPIs in treating patients with NERD. Fifteen studies with 6309 patients were included in the meta-analyses. For the rate of symptomatic relief, compared with control groups, all interventions except rabeprazole 5 mg significantly increased rate of symptomatic relief...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27580358/dexlansoprazole-delayed-release-orally-disintegrating-tablets-for-the-treatment-of-heartburn-associated-with-non-erosive-gastroesophageal-reflux-disease-and-the-maintenance-of-erosive-esophagitis
#10
Edward C Oldfield Iv, Parth J Parekh, David A Johnson
INTRODUCTION: Gastroesophageal reflux disease (GERD) is a common clinical condition afflicting millions of patients, whose prevalence continues to rise owing to the aging population and increasing burden of comorbid conditions, such as obesity. Currently, the mainstay of therapy for GERD is treatment with proton pump inhibitors (PPIs). Despite their overall efficacy, safety, and tolerability, there are still a considerable number of patients who fail treatment and have refractory symptoms to PPI therapy...
August 31, 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27534444/vonoprazan-versus-conventional-proton-pump-inhibitor-based-triple-therapy-as-first-line-treatment-against-helicobacter-pylori-a-multicenter-retrospective-study-in-clinical-practice
#11
Satoki Shichijo, Yoshihiro Hirata, Ryota Niikura, Yoku Hayakawa, Atsuo Yamada, Satoshi Mochizuki, Keigo Matsuo, Yoshihiro Isomura, Motoko Seto, Nobumi Suzuki, Hirobumi Suzuki, Shinzo Yamamoto, Takafumi Sugimoto, Tomoya Omae, Makoto Okamoto, Hirotsugu Watabe, Goichi Togo, Noriyuki Takano, Keisuke Fukui, Yuri Ito, Kazuhiko Koike
AIM: Vonoprazan is a potassium-competitive acid blocker, a new type of acid-suppressing drug, and has recently become available for peptic ulcers, gastroesophageal reflux disease, and Helicobacter pylori (H. pylori) eradication. Its efficacy for H. pylori eradication therapy isreported in a phase III randomized controlled trial, and in a single center study. However, the evidence for its efficacy and feasibility is still limited. MATERIAL AND METHODS: We performed a multicenter retrospective study of patients who received first-line H...
August 17, 2016: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/27514776/potassium-competitive-acid-blockers-advanced-therapeutic-option-for-acid-related-diseases
#12
Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake
Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reflux disease, represent a major health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment reached during the last 50years include 1) discovery of histamine H2-receptors and development of H2-receptor antagonists, 2) identification of H(+),K(+)-ATPase as the parietal cell proton pump and development of proton pump inhibitors (PPIs), and 3) identification of Helicobacter pylori (H. pylori) as the major cause of peptic ulcers and development of effective eradication regimens...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27495332/efficacy-of-transoral-incisionless-fundoplication-tif-for-the-treatment-of-gerd-a-systematic-review-with-meta-analysis
#13
Xiaoquan Huang, Shiyao Chen, Hetong Zhao, Xiaoqing Zeng, Jingjing Lian, Yujen Tseng, Jie Chen
BACKGROUND: The efficacy of transoral incisionless fundoplication (TIF) performed with the EsophyX device (Redmond, Washington, USA) and its long-term outcomes in gastresophageal reflux disease (GERD) are debated. We, therefore, performed a systematic review with meta-analysis of studies evaluating the role of TIF in GERD. METHODS: A systematic search of EMBASE, SCOPUS, PubMed, and the Cochrane Library Central was performed. All original studies reporting outcomes in GERD patients who underwent TIF were identified...
August 5, 2016: Surgical Endoscopy
https://www.readbyqxmd.com/read/27492962/vonoprazan-is-superior-to-proton-pump-inhibitors-in-healing-artificial-ulcers-of-the-stomach-post-endoscopic-submucosal-dissection-a-propensity-score-matching-analysis
#14
Daisuke Maruoka, Makoto Arai, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Osamu Yokosuka
BACKGROUND AND AIM: Proton pump inhibitors (PPI) are effective at healing artificial ulcers after endoscopic submucosal dissection (ESD) for gastric neoplasms; however, the efficacy of vonoprazan is not completely understood. The aim of the present study was to determine the healing effect of vonoprazan on artificial ulcers post-gastric ESD relative to PPI. METHODS: Thirty-five patients who underwent gastric ESD between April and November 2015 were treated with vonoprazan 20 mg/day for 4 weeks and subsequently underwent endoscopy for evaluation of ulcer size (V group)...
August 4, 2016: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/27446535/efficacy-of-alfacalcidol-and-alendronate-on-lumbar-bone-mineral-density-in-osteoporotic-patients-using-proton-pump-inhibitors
#15
Daisuke Asaoka, Akihito Nagahara, Mariko Hojo, Kenshi Matsumoto, Hiroya Ueyama, Kohei Matsumoto, Kentaro Izumi, Tsutomu Takeda, Hiroyuki Komori, Yoichi Akazawa, Yuji Shimada, Taro Osada, Sumio Watanabe
It has been indicated that proton pump inhibitor (PPI) use is associated with a loss of the anti-fracture efficacy of alendronate (AD). However, there are few prospective studies that have investigated the efficacy of AD on lumbar bone mineral density (BMD) in osteoporotic patients who are using PPIs. Thus, the aim of the present study was to investigate the efficacy of alfacalcidol (AC) and AD on lumbar BMD in osteoporotic patients using PPIs. A prospective, randomized, active control study enrolled such osteoporotic patients (age, ≥50 years)...
August 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27433347/a-randomized-crossover-pharmacodynamic-study-of-immediate-release-omeprazole-sodium-bicarbonate-and-delayed-release-lansoprazole-in-healthy-adult-volunteers
#16
Vijayalakshmi S Pratha, Thomas McGraw, William Tobin
Proton pump inhibitors (PPIs) effectively block gastric acid secretion and are the treatment of choice for heartburn. PPIs differ, however, in onset of action and bioavailability. In this single-center, open-label, three-way crossover study, onset of action of immediate-release omeprazole 20 mg/sodium bicarbonate 1100 mg (IR-OME) and delayed-release (DR) lansoprazole 15 mg was evaluated in 63 healthy fasting adults. Subjects were randomized to once daily IR-OME, or DR-lansoprazole, or no treatment for 7 days...
June 2016: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/27428571/vonoprazan-for-treatment-of-gastroesophageal-reflux-pharmacodynamic-and-pharmacokinetic-considerations
#17
Edoardo Savarino, Irene Martinucci, Manuele Furnari, Chiara Romana, Gaia Pellegatta, Alessandro Moscatelli, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Nicola de Bortoli, Corrado Blandizzi
INTRODUCTION: About 30-40% of GERD patients report an inadequate response to proton pump inhibitors (PPIs) due to their suboptimal pharmacological profiles. Recently, a new synthesized P-CABs, vonoprazan, showed higher suppression of gastric acid secretion as compared to lansoprazole. AREAS COVERED: This review provides an update on the pharmacokinetic properties of vonoprazan and their correlates with pharmacodynamics; preliminary data on the therapeutic efficacy of vonoprazan as compared to lansoprazole in GERD patients Expert opinion: At variance from all available PPIs, vonoprazan acts directly on H+,K+-ATPase irrespectively of its activity, providing a fast onset of action without requiring acid activation and specific administration timing...
August 8, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27313191/conversion-of-sleeve-gastrectomy-to-roux-en-y-gastric-bypass-an-audit-of-34-patients
#18
Tigran Poghosyan, Andrea Lazzati, David Moszkowicz, Divya Danoussou, Karina Vychnevskaia, Daniel Azoulay, Sebastien Czernichow, Claire Carette, Jean-Luc Bouillot
BACKGROUND: Weight loss failure and proton pomp inhibitor (PPI)-resistant gastroesophageal reflux diseases (GERD) after sleeve gastrectomy (SG) are frequently encountered. OBJECTIVES: The aim of this study was to evaluate the efficacy and risks of SG conversion to Roux-en-Y gastric bypass (RYGB) in the case of weight loss failure or severe GERD. SETTING: University hospitals. METHODS: Between March 2007 and December 2014, 34 patients with history of SG underwent RYGP...
March 2, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/27312992/a-meta-analysis-for-the-role-of-proton-pump-inhibitor-therapy-in-patients-with-laryngopharyngeal-reflux
#19
Chunhui Wei
We aimed to systematically review the randomized controlled trials (RCTs) regarding the therapeutic efficiency of proton pump inhibitor (PPI) therapy for laryngopharyngeal reflux (LPR). Randomized and placebo-controlled trials regarding the therapeutic efficacy of PPIs on LPR patients were systematically searched from MEDLINE, Cochrane Library, and EMBASE. Data were extracted from eligible studies meeting the inclusion criteria. Heterogeneity among these eligible studies was evaluated by the Q-statistic and I (2) test, based on which a fixed- or random-effects model was performed to pooled relative risks (RRs) for the response rate and standardized mean differences (SMDs) for reflux symptom index (RSI) and the reflux finding score (RFS)...
June 16, 2016: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/27289472/drug-interaction-between-clopidogrel-and-ranitidine-or-omeprazole-in-stable-coronary-artery-disease-a-double-blind-double-dummy-randomized-study
#20
Remo Holanda de Mendonça Furtado, Robert Patrick Giugliano, Celia Maria Cassaro Strunz, Cyrillo Cavalheiro Filho, José Antonio Franchini Ramires, Roberto Kalil Filho, Pedro Alves Lemos Neto, Alexandre Costa Pereira, Tânia Rúbia Rocha, Beatriz Tonon Freire, Elbio Antonio D'Amico, José Carlos Nicolau
BACKGROUND: Proton-pump inhibitors (PPIs) are often prescribed to patients receiving dual antiplatelet therapy (DAPT). However, this class of medication, especially omeprazole, has been associated with a reduction in clopidogrel efficacy, leading many clinicians to substitute omeprazole with ranitidine. OBJECTIVES: Our objective was to compare the antiplatelet effect of clopidogrel before and after the addition of omeprazole or ranitidine. METHODS: We measured platelet aggregability at baseline and after 1 week of clopidogrel 75 mg daily...
August 2016: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
keyword
keyword
45167
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"